Get the Stockscreener App
9.10
2.15%
-0.20
After Hours:
9.28
0.18
+1.98%
Forte Biosciences Inc stock is traded at $9.10, with a volume of 29,696.
It is down -2.15% in the last 24 hours and down -42.73% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
See More
Previous Close:
$9.30
Open:
$9.03
24h Volume:
29,696
Relative Volume:
0.35
Market Cap:
$58.18M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-8.75
EPS:
-1.04
Net Cash Flow:
$-28.71M
1W Performance:
-17.12%
1M Performance:
-42.73%
6M Performance:
+15.19%
1Y Performance:
-46.69%
1-Day Range:
$9.03
$9.895
1-Week Range:
$8.80
$11.38
52-Week Range:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
9.10 | 58.18M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 123.21B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 31.94B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.00B | 3.32B | -860.46M | -1.04B | -8.32 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update - MarketBeat
Forte Biosciences Stock Down 20% But Insiders Still In US$92k Profit - Simply Wall St
Pre-market Movers: ISPC, TH, IVVD, TOVX... - RTTNews
(FBRX) On The My Stocks Page - Stock Traders Daily
Stock Traders Buy Large Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
Forte Biosciences Target of Unusually Large Options Trading (NASDAQ:FBRX) - Defense World
One Forte Biosciences Insider Raised Stake By 273% In Previous Year - Yahoo Finance
Best Stocks Under $20 Right Now - Benzinga
Where are the Opportunities in (FBRX) - Stock Traders Daily
Stock Traders Buy High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings -February 03, 2025 at 09:03 am EST - Marketscreener.com
Autoimmune Biotech Forte Lines Up Strategic Presentations at Major Healthcare Investment Forums - StockTitan
(FBRX) Proactive Strategies - Stock Traders Daily
CSG Forte Wins TSG Real Transaction Metrics Awards for Second Consecutive Year - Yahoo Finance
Forte Biosciences expands equity incentive plan By Investing.com - Investing.com Australia
TD Cowen initiates Forte Biosciences stock with Buy rating - MSN
Forte Biosciences expands equity incentive plan - MSN
Traders Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
Meiwu Technology (NYSE:WNW) Stock Price Down 13.2% – Here’s Why - Defense World
Forte Biosciences (NASDAQ:FBRX) Coverage Initiated by Analysts at TD Cowen - Defense World
TD Cowen initiates Forte Biosciences stock with Buy rating By Investing.com - Investing.com Australia
Atopic Dermatitis Drugs Market Trends Analysis Report - GlobeNewswire
(FBRX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX) - Defense World
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
(FBRX) Technical Data - Stock Traders Daily
Investors Purchase Large Volume of Put Options on Evelo Biosciences (NASDAQ:EVLO) - Defense World
Investors Buy High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
(FBRX) Long Term Investment Analysis - Stock Traders Daily
100 cell and gene therapy leaders to watch in 2025 - Drug Discovery & Development
Why Forte Biosciences (FBRX) Stock Is Trading Lower - Benzinga
CBD Life Sciences Inc. (OTCMKTS:CBDL) Short Interest Up 8,233.3% in November - Defense World
Traders Buy Large Volume of Call Options on Quantum-Si (NASDAQ:QSI) - Defense World
Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors - The Manila Times
Trading (FBRX) With Integrated Risk Controls - Stock Traders Daily
FBRX Stock Soars to 52-Week High, Reaching $24.46 By Investing.com - Investing.com Nigeria
Forte Biosciences’ $53 Million Equity Financing - Global Legal Chronicle
Biopharma Takes on Deadly Brain Cancer After Decades of Failure - BioSpace
(FBRX) Trading Report - Stock Traders Daily
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going - MSN
FBRX Stock Soars to 52-Week High, Reaching $21.47 - Investing.com India
FBRX Stock Soars to 52-Week High, Reaching $21.47 By Investing.com - Investing.com UK
Forte Biosciences Sets R&D Day to Showcase FB102 Autoimmune Treatment Pipeline | FBRX Stock News - StockTitan
Forte Biosciences CFO acquires $124,997 in company stock By Investing.com - Investing.com Canada
Forte Biosciences CFO acquires $124,997 in company stock - Investing.com
More than $50M raised by publicly traded drug developer - The Business Journals
Dallas' Forte Biosciences Announces $53M Private Placement From Leading Healthcare Investors - dallasinnovates.com
Forte Biosciences Stock More Than Doubles On Oversubscribed $53M Private Placement: Retail Goes Wild - MSN
EDIT Stock Drops Amid Market Volatility in Biotech Sector - GuruFocus.com
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):